NYSE:MRKPharmaceuticals
Merck (MRK) Stock May Be 35% Undervalued After Cancer Vaccine Data
Merck stock has delivered a strong 130.2% return over the past 5 years, yet its valuation picture is split, with a Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market multiples lean the other way.
Over 5 years, Merck has returned 130.2%, which puts recent enthusiasm for the story firmly in focus for anyone thinking about new money going into the stock.
Recent progress in oncology, including the personalized mRNA melanoma vaccine with Moderna and broader use of...